Clasmatodendrosis correlating with periventricular hyperintensity in mixed dementia

2002 ◽  
Vol 52 (3) ◽  
pp. 378-381 ◽  
Author(s):  
Demetrios J. Sahlas ◽  
Juan M. Bilbao ◽  
Richard H. Swartz ◽  
Sandra E. Black
Keyword(s):  
Mixed Dementia ◽  
Periventricular Hyperintensity

Neuropsychiatric Symptoms and Antipsychotic Therapy in the Elderly Patients with Dementia

Psychiatry ◽  
2020 ◽  
Vol 18 (4) ◽  
pp. 6-15
Author(s):  
I. V. Kolykhalov
Keyword(s):  
Neuropsychiatric Symptoms ◽  
The Elderly ◽  
Psychotic Symptoms ◽  
Mixed Dementia ◽  
Short Term ◽  
Antipsychotic Therapy ◽  
Dementia Patients ◽  
Frequency Of Use ◽  
Number Of Patients ◽  
High Incidence

The objective of the study was to investigate syndromal-nosological specificities of neuropsychiatric symptoms (NPS) and the frequency of use of antipsychotics in patients with various types of dementias, institutionalized to geriatric units of mental hospitals.Patients and methods: a total of 106 in-patients of three psychogeriatric units were examined. The median age of patients is 75 years [69; 80].The diagnostic distribution of patients at the time of the examination was as follows: in 33 subjects (31.1%) Alzheimer’s disease (AD) was diagnosed, in 25 (23.6%) - mixed dementia (MD), in 32 (30.2%) - vascular dementia (VD) and in 16 (15.1%) patients had dementia of complex origin (DCO).Results: a high incidence (54.7%) of NPS was found in patients with dementia of various origins. The greatest number of patients with behavioral and psychotic symptoms was found in AD and MD. The proportion of dementia patients with such disorders in each of these types of dementia is about 70%, while in CGD and VD, the proportion of patients with NPS is noticeably smaller (30% and 40%, respectively). For the treatment of NPS, antipsychotics were most often prescribed, but their use caused adverse events (AEs) in 1/3 of cases. Patients with VD are most susceptible to the development of AE, and AD patients are the least susceptible.Conclusion: the study showed that NPS are one of the important components of dementia, regardless of the nosology and stage of the disease. The treatment of NPS in dementia is particularly challenging because, although the symptoms cause significant distress, there are currently no effective alternative therapies. The risk of AE can be minimized by carefully considering the indications for prescribing antipsychotics and their short-term use, regular monitoring of the patient’s condition, and educating caregivers.

Cholinesterase Inhibitors Modulate Autonomic Function in Patients with Alzheimer´s Disease and Mixed Dementia

2013 ◽  
Vol 10 (5) ◽  
pp. 476-481 ◽  
Author(s):  
Filipi Leles da Costa Dias ◽  
Rose Mary Ferreira Lisboa da Silva ◽  
Edgar Nunes de Moraes ◽  
Paulo Caramelli
Keyword(s):  
Cholinesterase Inhibitors ◽  
Autonomic Function ◽  
Mixed Dementia

An open-label extension trial of galantamine in patients with probable vascular dementia and mixed dementia

2003 ◽  
Vol 25 (6) ◽  
pp. 1765-1782 ◽  
Author(s):  
Timo Erkinjuntti ◽  
Alexander Kurz ◽  
Gary W Small ◽  
Roger Bullock ◽  
Sean Lilienfeld ◽  
...  
Keyword(s):  
Vascular Dementia ◽  
Mixed Dementia ◽  
Open Label ◽  
Open Label Extension ◽  
Extension Trial

P3-426: Omega-3 polyunsaturated fatty acids and mixed dementia

2011 ◽  
Vol 7 ◽  
pp. S651-S652
Author(s):  
Ivan Culum ◽  
J.B. Orange ◽  
Dorothy Forbes ◽  
Michael Borrie
Keyword(s):  
Fatty Acids ◽  
Polyunsaturated Fatty Acids ◽  
Omega 3 ◽  
Mixed Dementia

Cerebellar atrophy as a CT marker for mixed dementia

1992 ◽  
Vol 31 (5) ◽  
pp. 520-524 ◽  
Author(s):  
Laurie L. Barclay ◽  
Patricia A. Brady
Keyword(s):  
Cerebellar Atrophy ◽  
Mixed Dementia

scholarly journals Correlation of NO Metabolites and 8-Iso-Prostaglandin F 2a With Periventricular Hyperintensity Severity

2004 ◽  
Vol 24 (9) ◽  
pp. 1659-1663 ◽  
Author(s):  
Hiroshi Shibata ◽  
Toru Nabika ◽  
Hidehiko Moriyama ◽  
Junichi Masuda ◽  
Shotai Kobayashi
Keyword(s):  
Prostaglandin F ◽  
Periventricular Hyperintensity

Clinical Features Distinguishing Large Cohorts with Possible AD, Probable AD, and Mixed Dementia

1993 ◽  
Vol 41 (1) ◽  
pp. 31-37 ◽  
Author(s):  
Jody Corey-Bloom ◽  
Douglas Galasko ◽  
C. Richard Hofstetter ◽  
J. Edward Jackson ◽  
Leon J. Thal
Keyword(s):  
Clinical Features ◽  
Mixed Dementia

The Diagnosis of "Mixed" Dementia in the Consortium for the Investigation of Vascular Impairment of Cognition (CIVIC)

2000 ◽  
Vol 903 (1 VASCULAR FACT) ◽  
pp. 522-528 ◽  
Author(s):  
K. ROCKWOOD ◽  
C. MACKNIGHT ◽  
C. WENTZEL ◽  
S. BLACK ◽  
R. BOUCHARD ◽  
...  
Keyword(s):  
Mixed Dementia

Alzheimer’s disease and its related Dementia types: A review on their management via nanotechnology based therapeutic strategies

2021 ◽  
Vol 18 ◽  
Author(s):  
Panoraia I. Siafaka ◽  
Gökce Mutlu ◽  
Neslihan Üstündağ Okur
Keyword(s):  
Alzheimer’S Disease ◽  
Drug Delivery ◽  
Alzheimer's Disease ◽  
Vascular Dementia ◽  
Drug Delivery Systems ◽  
Delivery Systems ◽  
The Body ◽  
Daily Routine ◽  
Mixed Dementia ◽  
The Brain

Background: Dementia and its related types such as Alzheimer’s disease, vascular dementia and mixed dementia belong to brain associated diseases, resulting in long-term progressive memory loss. These diseases are so severe that can affect a person's daily routine. Up to date, treatment of de- mentias is still an unmet challenge due to their complex pathophysiology and unavailable efficient pharmacological approaches. The use of nanotechnology based pharmaceutical products could possibly improve the management of dementia given that nanocarriers could more efficiently deliver drugs to the brain. Objective: The objective of this study is to provide the current nanotechnology based drug delivery systems for the treatment of various dementia types. In addition, the current diagnosis biomarkers for the mentioned dementia types along with their available pharmacological treatment are being dis- cussed. Method: An extensive review of the current nanosystems such as brain drug delivery systems against Alzheimer’s disease, vascular dementia and mixed dementia was performed. Moreover, nan- otheranostics as possible imaging markers for such dementias were also reported. Results: The field of nanotechnology is quite advantageous for targeting dementia given that nanoscale drug delivery systems easily penetrate the blood brain barrier and circulate in the body for prolonged time. These nanoformulations consist of polymeric nanoparticles, solid lipid nanoparticles, nanostruc- tured lipid carriers, microemulsions, nanoemulsions, and liquid crystals. The delivery of the nan- otherapeutics can be achieved via various administration routes such as transdermal, injectable, oral, and more importantly, through the intranasal route. Nonetheless, the nanocarriers are mostly limited to Alzheimer’s disease targeting; thus, nanocarriers for other types of dementia should be developed. Conclusion: To conclude, understanding the mechanism of neurodegeneration and reviewing the cur- rent drug delivery systems for Alzheimer’s disease and other dementia types are significant for medical and pharmaceutical society to produce efficient therapeutic choices and novel strategies based on mul- tifunctional and biocompatible nanocarriers, which can deliver the drug sufficiently into the brain.

Sign in / Sign up

Export Citation Format

Share Document